Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.
Bio-Techne
WHERE SCIENCE INTERSECTS INNOVATIONTM
![Immunocytochemistry/Immunofluorescence: Tat-Beclin 1 D11 Autophagy Inducing Peptide [NBP2-49888] - HeLa GFP-LC3B cells were treated with Tat-D11, Tat-L11, Tat-Beclin 1 or Tat-L11S for 1.5 hours. Thereafter, the cells were stained using NeuroTrace Red or DAPI and analyzed employing fluorescent microscopy. Note the higher number of autophagosomes/GFP-LC3B+ puncta in the images of Tat-D11 and Tat-L11 treated cells when compared to Tat-Beclin 1 and Tat-L11S treated cells.](http://images.novusbio.com/fullsize2/Tat-Beclin-1-D11-Autophagy-Inducing-Peptide-Immunocytochemistry-Immunofluorescence-NBP2-49888-img0002.jpg "Immunocytochemistry/Immunofluorescence: Tat-Beclin 1 D11 Autophagy Inducing Peptide [NBP2-49888] - HeLa GFP-LC3B cells were treated with Tat-D11, Tat-L11, Tat-Beclin 1 or Tat-L11S for 1.5 hours. Thereafter, the cells were stained using NeuroTrace Red or DAPI and analyzed employing fluorescent microscopy. Note the higher number of autophagosomes/GFP-LC3B+ puncta in the images of Tat-D11 and Tat-L11 treated cells when compared to Tat-Beclin 1 and Tat-L11S treated cells.")
![In vitro assay: Tat-Beclin 1 D11 Autophagy Inducing Peptide - Retroinverso form [NBP2-49888] - Analysis of lysates from HeLa cells that were left untreated (blank) or were treated with 10-20 uM each of Tat-D11, Tat-L11, Tat-Beclin 1 or Tat-L11S. The lysates were analyzed for the expression of LC3-1/LC3-II and SQSTM1/p62 using 2 ug/mL each of anti-LC3B (NB100-2220) and anti-SQSTM1/p62 (MAB8028) respectively. Anti-Actin (AF4000) was used as a loading control. TatD11 exhibited superior induction of LC3-II and down-regulation of p62 protein when compared to other treatment and control groups.](http://images.novusbio.com/fullsize2/Tat-Beclin-1-D11-Autophagy-Inducing-Peptide---Retroinverso-form-Western-Blot-NBP2-49888-img0001.jpg)
![In vivo assay: Tat-Beclin 1 D11 Autophagy Inducing Peptide - Retroinverso form [NBP2-49888] - In vivo dose study in 10wk old C57BL/6J mice. Either 1mg/kg or 10mg/kg IP once daily was administered for 2 days, mice were sacrificed, kidneys prepared for Western blot analysis. Lysosomal inhibitor bafilomycin A1 was used to provide a measurement of autophagic flux. *vehicle is scrambled tat-beclin (NBP2-49887-5mg). Image from verified customer review.](http://images.novusbio.com/fullsize2/Tat-Beclin-1-D11-Autophagy-Inducing-Peptide---Retroinverso-form-In-vivo-assay-NBP2-49888-img0004.jpg)